Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  THERAPEUTIC APHERESIS
A US Market Report

This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, Rheumatology Disorders, and Others. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for this market. The report profiles 19 companies including many key and niche players such as CaridianBCT, Inc., Fenwal, Inc., Fresenius Medical Care North America, Haemonetics Corporation, HemaCare Corporation, Hospital Clinical Services Group, Inc., and Therakos, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1237  PAGES:    87
PRICE:    $4500  DATE:       September 2010
COMPANIES:  19  MARKET DATA TABLES:   12
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  THERAPEUTIC APHERESIS (Complete Report) Pages : 87   | $4500
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......15 $100  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2  
   Data Interpretation & Reporting Level.......3
Quantitative Techniques & Analytics.......3
Product Definitions and Scope of Study.......3
  
   A Peek into the Above-Mentioned Procedures.......4
Plasmapheresis.......4
Immunoadsorption.......4
Erythrocytapheresis.......4
Plateletpheresis.......4
Leukapheresis.......4
  
   Photopheresis.......5
Lipidpheresis.......5
  
  2. MARKET ANALYSIS........62 $200  
   A Current & Future Analysis........6
A Promising Outlook........6
2$200
  3. MARKET TRENDS........83 $300  
   Apheresis Process Leads to Rise in Platelet Donors........8
Therapeutic Apheresis Devices – A Perplexing Market........8
Plateletpheresis: The Treatment of Choice for Patients........8
1$100
   Photopheresis Market Growing at a High Rate........9
Vendors’ Attitude Hampers Growth Prospects of Therapeutic Apheresis........9
1$100
   Developing New Applications for Therapeutic Apheresis is the Need of the Hour........10
CFA – An Effective Way to Pull Up Cold Hemagglutinin Disease........10
1$100
  4. COMPETITIVE SCENARIO........117 $1750  
   Overview........11
Technology: The Only Key for Success........11
CaridianBCT: The World Leader........11
1$100
   Market Share Trends – A Historic Review........12
By Procedures (Revenues)........12
Table 1: US Market for Therapeutic Apheresis (2002 & 2005): Percentage Breakdown of Revenues by Company for Gambro BCT, Therakos, Fresenius Hemocare, Kaneka Pharma America Corporation, Baxter Transfusion Therapies, and Others (includes corresponding Graph/Chart)........12
1$350
   By Procedures (Number of Procedures)........13
Table 2: US Market for Therapeutic Apheresis (2002 & 2005): Percentage Breakdown of Number of Procedures by Company for Gambro BCT, Therakos, Fresenius HemoCare, Haemonetics, Baxter Transfusion Therapies, and Others (includes corresponding Graph/Chart)........13
1$350
   By Neurology Disorders (Revenues)........14
Table 3: US Market for Therapeutic Apheresis in Neurological Disorders (2002 & 2005): Percentage Breakdown of Revenues by Company for Gambro BCT, Fresenius HemoCare, Haemonetics, and Others (includes corresponding Graph/Chart)........14
1$350
   By Neurology Disorders (Number of Procedures)........15
Table 4: US Market for Therapeutic Apheresis in Neurological Disorders (2002 & 2005): Percentage Breakdown of Number of Procedures by Company for Gambro BCT, Fresenius HemoCare, Haemonetics, and Others (includes corresponding Graph/Chart)........15
1$350
   By Hematology and Oncology Disorders (Revenues)........16
Table 5: US Market for Therapeutic Apheresis in Hematology and Oncology Disorders (2002 & 2005): Percentage Breakdown of Revenues by Company for Gambro BCT, Therakos, Fresenius HemoCare, Baxter Transfusion Therapies, and Others (includes corresponding Graph/Chart)........16
1$350
   By Hematology and Oncology (Number of Procedures)........17
Table 6: US Market for Therapeutic Apheresis in Hematology and Oncology Disorders in (2002 & 2005): Percentage Breakdown of Number of Procedures by Company for Gambro BCT, Fresenius HemoCare, Baxter Transfusion Therapies, Therakos, and Others (includes corresponding Graph/Chart)........17
1$350
  5. MARKET OVERVIEW & OUTLOOK........183 $300  
   Market Drivers........18
New Reimbursement Policies Create Growth Opportunities for Therapeutic
  Apheresis........18
1$100
   Increased Industry Consolidation Drives Research........19
Development of New Technology........19
Research Unveils Novel Applications........19
Market Restraints........19
Lack of Awareness Restrains Growth........19
Therapeutic Apheresis Costs Still a Concern........19
1$100
   Market Challenges........20
Development of Inexpensive Apheresis Therapy........20
Scarcity of Qualified Donors........20
Pediatry: An Untapped Opportunity........20
1$100
  6. REGULATORY ENVIRONMENT........211 $100  
   Regulatory Environment........21
1$100
  7. PRODUCT OVERVIEW........226 $450  
   Therapeutic Apheresis: An Introduction........22
Overview of Therapeutic Apheresis........22
Blood Components........22
1$100
   Apheresis and Therapeutic Apheresis: The Difference........23
Therapeutic Apheresis Process........23
Duration, Frequency, and Efficiency of Therapeutic Apheresis........23
Segregation of Blood Components........23
1$100
   Centrifugation........24
Filtration........24
History........24
1$100
   Types of Therapeutic Apheresis Procedures........25
Plasmapheresis........25
Erythrocytapheresis........25
Plateletpheresis........25
Leukapheresis........25
Stem Cell Apheresis........25
1$100
   Photopheresis........26
Lipidpheresis........26
Cytapheresis........26
Immunoadsorption........26
Rheopheresis........26
1$100
   Therapeutic Apheresis is Remedial for Various Diseases........27
1$100
  8. PRODUCT TRENDS AND ISSUES........283 $300  
   Therapeutic Plasmapheresis with Fresh Frozen Plasma (FFP) Replacement........28
Risks Associated with Therapeutic Apheresis........28
1$100
   Categories of Indications for Therapeutic Apheresis........29
Plasma Exchange and Plasmapheresis: The Difference........29
Applications of Plasma Exchange........29
1$100
   Chronic Diseases........30
Acute Self-Limited Disease........30
Emerging Applications........30
1$100
  9. PRODUCT AND TECHNOLOGICAL DEVELOPMENTS........313 $300  
   CaridianBCT Introduces Spectra Optia® System Mononuclear Cell Collection
  Protocol........31
Golden Meditech Company to Launch Model 3000H Plasma Exchange System........31
HemoCleanse to Develop Novel Plasmapheresis Device........31
1$100
   Aethlon Develops a New Device to Remove HIV........32
Therapeutic Plasmapheresis for Treatment of Autoimmune Diseases........32
1$100
   Occulogix Offers Blood-Filtering Treatment for Macular Degeneration........33
1$100
  10. RECENT INDUSTRY ACTIVITY........344 $400  
   Therakos Obtains FDA Approval for THERAKOSTM CELLEXTM Photopheresis System........34
Biotest Acquires Talecris’ Plasma Collection Unit........34
Kawasumi Laboratories to Take Over Sales Rights from Kuraray........34
Sheikh Khalifa Medical City Launches Therapeutic Apheresis Program........34
1$100
   Asahi Kasei Kuraray Medical to Open New Laboratory........35
Gambro Changes Name to CaridianBCT........35
Therakos Obtains CE Mark in Europe........35
1$100
   Baxter Divests Transfusion Therapies Business........36
SCSG Gets Hold of Fresenius Medical Care Extracorporeal Alliance........36
Rheologics Technologies Takes Over Cardiodyne Electronics........36
Biotest Obtains Business Unit of Nabi BioPharmaceuticals........36
Gambro BCT Receives FDA Clearance for Spectra Optia System........36
1$100
   MedaSorb Receives Rights for Blood Processing........37
Fresenius Medical Care Takes Over Renal Care........37
Haemonetics Signs Acquisition Agreement with Arryx........37
Cerus Receives Rights for INTERCEPT Blood System........37
Blood Systems to Implement Gambro BCT 7-day platelets........37
1$100
  11. STRATEGIC CORPORATE DEVELOPMENTS IN RECENT PAST........387 $550  
   Renal Care Pockets Bay Area Mobile Apheresis Program........38
Haemonetics Pacts with FMCEA........38
PhereSys and ACGT Ink Consulting Services Pact........38
CHF Forges a Service Provider Pact with FMCEA........38
1$100
   Otsuka America Inks a Pact with HemaCare........39
Gambro Acquires Ivex........39
Fresenius HemoCare Becomes a Part of Fresenius Kabi........39
Alpha Therapeutic Sells Assets to Probitas Pharma and Baxter........39
Gambro Signs Agreement with The American Red Cross........39
1$100
   Gambro Receives Contract from NBS........40
FMC-EA Inks Deal with Allina Hospitals........40
Gambro Starts a New Company, Navigant Biotechnologies........40
Gambro’s Vista™ Receives Approval from FDA........40
Gambro’s New Anticoagulant Solution Receives FDA Approval........40
1$100
   Gambro BCT Receives FDA Clearance for New Filter Tubing Sets Developed by Pall........41
Gambro Launches Trima Accel Automated Blood Collection System........41
Fresenius HemoCare Acquires PROSORBA® Column from Cypress Bioscience........41
Gambro Buys the Assets of Sanguistech........41
1$100
   Haemonetics Inks Purchase Agreement with Alpha Therapeutic Corp........42
Gambro Joins Forces with the Walter Reed Army Institute of Research........42
Gambro Collaborates with Dendreon for Commercialization of Therapeutic
  Vaccines........42
Gambro AB Enters into a Partnership with Sangart........42
1$100
   WakeMed Awards a Contract to HemaCare’s Subsidiary........43
HemaCare’s Subsidiary Coral in Agreement with CMH........43
BioTransplant Inks an Exclusive Distribution Agreement with Gambro BCT........43
Gambro BCT Receives US Patent for its Pathogen Inactivation Technology........43
1$100
   Gambro’s Trima Receives Approval from The Japanese Red Cross Society........44
Gambro BCT Test Launches the Vista™ Information System........44
1$100
  12. FOCUS ON SELECT PLAYERS........453 $300  
   CaridianBCT, Inc.........45
Fenwal, Inc.........45
Fresenius Medical Care North America (FMCNA)........45
1$100
   Haemonetics Corp.........46
HemaCare Corp.........46
Hospital Clinical Services Group, Inc. (HCSG)........46
1$100
   Therakos, Inc.........47
1$100
  13. MARKET PERSPECTIVE........48   
   Table 7: US Recent Past, Current & Future Market Analysis for Therapeutic Apheresis by Procedure - Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis and Lipidpheresis Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2007through 2015(includes corresponding Graph/Chart)........481$350
   Table 8: US Historic Review for Therapeutic Apheresis by Procedure - Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis and Lipidpheresis Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2001 through 2006 (includes corresponding Graph/Chart)........491$350
   Table 9: US 10-Year Perspective for Therapeutic Apheresis by Procedure – Percentage Breakdown of Revenues for Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis and Lipidpheresis Markets Independently Analyzed for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........501$350
   Table 10: US Recent Past, Current & Future Market Analysis for Therapeutic Apheresis by End Use - Neurology Disorders, Hematology and Oncology Disorders, Rheumatology Disorders and Other Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2007 through 2010 (includes corresponding Graph/Chart)........511$350
   Table 11: US Historic Review for Therapeutic Apheresis by Disorder Type – Neurology, Hematology and Oncology, Rheumatology and Others Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2001 through 2006 (includes corresponding Graph/Chart)........521$350
   Table 12: US 10-Year Perspective for Therapeutic Apheresis by End Use – Percentage Breakdown of Revenues for Neurology Disorders, Hematology and Oncology Disorders, Rheumatology Disorders and Other Markets Independently Analyzed for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........531$350
COMPETITION 30$995
  
Total Companies Profiled: 19 (including Divisions/Subsidiaries - 22)

Region/Country                 Players


The United States                  18   
Europe                              4
Germany                             3
Rest of Europe                      1
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.